Clinical trials: MAFLD
Metabolic Associated Fatty Liver Disease
MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes
Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis.
- Trial name
- NCT04761900
- Testing
- the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases
- Volunteers
- 3,372 people
- Sponsor
- Ningbo No. 1 Hospital
Metabolic Associated Fatty Liver Disease, Bariatric Surgery Candidate
Short Term Outcome of Metabolic Associated Fatty Liver Disease (MAFLD) in Patients Undergoing Bariatric Surgery
Obesity has become one of the most critical public health problems in economically developed and developing countries in the world.
- Trial name
- NCT06180928
- Volunteers
- 50 people
- Sponsor
- Assiut University
MAFLD in Prediabetes and Diabetes
Effect of SGLT2 Inhibitor on Metabolic-Dysfunction-Associated Fatty Liver Disease in Patients With Insulin Resistance
Metabolic-dysfunction-associated fatty liver disease (MAFLD) has evolved as a major health problem recently. Discovering ways to prevent or delay the progression of MAFLD has become a global focus.
- Trial name
- SGLT2 (NCT07891234)
- Testing
- Dapagliflozin 5Mg Tab, Metfomin 500 mg, Dapagliflozin (10mg Tab)
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Sherihan AboElyazed Mohamed Khalil
Type 2 Diabetes, Obesity
Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM
This is an exploratory study evaluating CS0159 in combination with Semaglutide in metabolic dysfunction-associated fatty liver disease (MAFLD) patients with obesity and type 2 diabetes (T2DM).
- Conditions
- Type 2 Diabetes, Obesity, Non-alcoholic Fatty Liver Disease
- Trial name
- NCT07570810
- Testing
- CS0159, Semaglutide
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Non-Alcoholic Fatty Liver Disease
The Effects of Tai Chi on Metabolic Dysfunction-associated Fatty Liver Disease in Middle-Aged and Older Adults
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a liver condition primarily driven by metabolic dysfunctions that may progress to hepatitis, cirrhosis, and hepatocellular carcinoma.
- Trial name
- NCT06717828
- Testing
- Tai Chi Exercise, Regular Exercise, Control
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fujian Provincial Hospital
Metabolic Disease, Fatty Liver, Nonalcoholic
Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease)
Given the current increase in the incidence of dyslipidemia and obesity in the general population, there is a strong interest in identifying dietary factors capable of preventing the onset of metabolic diseases or at least…
- Trial name
- NCT05558592
- Testing
- Dietary supplementation with fresh oranges, Balanced Diet without oranges
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
MAFLD, AI (Artificial Intelligence)
AI Models vs Non-Invasive Fibrosis Scores in MAFLD Diagnosis
This study evaluates the accuracy of artificial intelligence (AI) models using FibroScan and clinical data to predict hepatic fibrosis in Egyptian patients with metabolic-associated fatty liver disease (MAFLD).
- Trial name
- MAFLD-AI (NCT07305636)
- Where
- Egypt
- Volunteers
- 522 people
- Sponsor
- Tanta University
MAFLD, Liver Fibrosis
Incidence of Liver Disease-Related Outcomes in People With HIV
Antiretroviral therapy can effectively control the replication of HIV, prolong the lifespan of patients infected with HIV, and improve their quality of life.At the same time, non-AIDS-related diseases such as diabetes and chronic…
- Conditions
- MAFLD, Liver Fibrosis, MASH, HIV
- Trial name
- PWH (NCT06940375)
- Testing
- Abdominal ultrasound , Fibroscan and body composition analysis examination
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Shanghai Public Health Clinical Center
Non-alcoholic Fatty Liver Disease, Obesity
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
STUDY OBJECTIVE: To explore the clinical efficacy and safety of liraglutide in obesity combined with metabolism-associated fatty liver disease (MAFLD).
- Trial name
- NCT06501326
- Testing
- Liraglutide, Orlistat
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Affiliated Hospital of Nantong University
MAFLD, Fatty Liver
Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)
This RCT investigates the impact of Ganoderma lucidum on antioxidant staus, NRF2 levels and lipid metabolism in individuals with Metabolic Associated Fatty Liver Disease.
- Conditions
- MAFLD, Fatty Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic
- Trial name
- GL-MAFLD-NFR2 (NCT07564947)
- Testing
- Ganoderma lucidum
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- University of Agriculture, Peshawar
MASLD
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase II clinical trial that consists of two parts.
- Trial name
- NCT07024212
- Testing
- DR10624 Injection
- Where
- 4 sites in China, Hong Kong
- Volunteers
- 110 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
MAFLD
Glucose Disposal Rate as a Metric for Detection of Metabolic Associated Fatty Liver
A 12-month prospective observational cohort study assessing eGDR's utility in diagnosing MAFLD (via FibroScan® CAP ≥248 dB/m) and correlating it with steatosis/fibrosis severity.
- Trial name
- NCT06923215
- Volunteers
- 30 people
- Sponsor
- Assiut University
Metabolic Dysfunction-associated Fatty Liver Disease
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most common chronic liver disease worldwide. Timely therapeutic intervention for MAFLD is crucial for improving patient prognosis and preventing its…
- Trial name
- NCT07085962
- Testing
- Calculus bovis sativus
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huazhong University of Science and Technology
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Mediterranean Diet
Identification and Characterization of At-risk MASLD in Turkish Adults
MASLD is with 25% the most prevalent liver disorder in Western society and is associated with overweight, obesity, metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVD).
- Conditions
- MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), Mediterranean Diet, Lifestyle (Sedentary Behavior and Physical Activity), Vitamin D Deficiency
- Trial name
- NCT07548970
- Where
- Turkey (Türkiye)
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Fatty Liver, NAFLD
Effect of CoQ10 on the Outcome of MAFLD Patients
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors.
- Trial name
- NCT05984745
- Testing
- Coenzyme Q10 Forte® capsules
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Type 2 Diabetes Mellitus (T2DM)
Adiponectin in Patients With Metabolic Disorders
Background. Metabolic dysfunction-associated fatty liver disease (MAFLD/MASLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with insulin resistance.
- Trial name
- NCT07539584
- Testing
- SGLT2 inhibitor, GLP-1 RA
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI)
Metabolic Dysfunction-Associated Fatty Liver Disease
CPET-based HIIT for MAFLD
High-intensity interval training (HIIT), as an individualized exercise training mode based on cardiopulmonary exercise testing (CPET), is characterized by high-intensity training sessions interspersed with short rest periods.
- Trial name
- CEPHIT (NCT07177963)
- Testing
- HIIT, No specific exercise intervention.
- Where
- 5 sites in China
- Volunteers
- 54 people
- Sponsor
- Tang Yida
Chronic Hepatitis B, Non-alcoholic Fatty Liver Disease
Chronic Hepatitis B Patients With Concurrent MAFLD: Cohort Study and Exercise Intervention.
In Taiwan, HBV infection is endemic in the adult population. With the westernization of eating habit and lifestyle, metabolic syndrome and related non-alcoholic fatty liver diseases (NAFLD, newly proposed as metabolic dysfunction…
- Trial name
- NCT05956379
- Testing
- exercise
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Metabolic-associated Fatty Liver Disease (MAFLD)
Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
Metabolic-associated fatty liver disease (MAFLD) is a chronic progressive liver disease caused by nutrient excess and insulin resistance (IR) in genetically susceptible individuals.
- Trial name
- NCT06798948
- Testing
- Combination of cynara scolymus, silybum marianum, curcuma longa, and glycyrrhiza glabra
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Li Lab,MD
MAFLD, HEPATITIS B CHRONIC
Comparison of a Handheld Elastography Device With iLivTouch in Chronic Liver Disease Patients
This single-center cross-sectional study aims to evaluate the agreement between a handheld elastography device and the iLivTouch transient elastography system for the noninvasive assessment of liver fibrosis and steatosis in…
- Trial name
- NCT07242404
- Volunteers
- 224 people
- Sponsor
- Hong You